Research ArticleBasic Science Investigations
In Vivo Biodistribution of No-Carrier-Added 6-18F-Fluoro-3,4-Dihydroxy-l-Phenylalanine (18F-DOPA), Produced by a New Nucleophilic Substitution Approach, Compared with Carrier-Added 18F-DOPA, Prepared by Conventional Electrophilic Substitution
Willem-Jan Kuik, Ido P. Kema, Adrienne H. Brouwers, Rolf Zijlma, Kiel D. Neumann, Rudi A.J.O. Dierckx, Stephen G. DiMagno and Philip H. Elsinga
Journal of Nuclear Medicine January 2015, 56 (1) 106-112; DOI: https://doi.org/10.2967/jnumed.114.145730
Willem-Jan Kuik
1Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
Ido P. Kema
2Department of Laboratory Medicine, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
Adrienne H. Brouwers
1Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
Rolf Zijlma
1Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
Kiel D. Neumann
3Ground Fluor Pharmaceuticals, Inc., Lincoln, Nebraska; and
Rudi A.J.O. Dierckx
1Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
Stephen G. DiMagno
4Department of Chemistry, University of Nebraska, Lincoln, Nebraska
Philip H. Elsinga
1Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 56, Issue 1
January 1, 2015
In Vivo Biodistribution of No-Carrier-Added 6-18F-Fluoro-3,4-Dihydroxy-l-Phenylalanine (18F-DOPA), Produced by a New Nucleophilic Substitution Approach, Compared with Carrier-Added 18F-DOPA, Prepared by Conventional Electrophilic Substitution
Willem-Jan Kuik, Ido P. Kema, Adrienne H. Brouwers, Rolf Zijlma, Kiel D. Neumann, Rudi A.J.O. Dierckx, Stephen G. DiMagno, Philip H. Elsinga
Journal of Nuclear Medicine Jan 2015, 56 (1) 106-112; DOI: 10.2967/jnumed.114.145730
In Vivo Biodistribution of No-Carrier-Added 6-18F-Fluoro-3,4-Dihydroxy-l-Phenylalanine (18F-DOPA), Produced by a New Nucleophilic Substitution Approach, Compared with Carrier-Added 18F-DOPA, Prepared by Conventional Electrophilic Substitution
Willem-Jan Kuik, Ido P. Kema, Adrienne H. Brouwers, Rolf Zijlma, Kiel D. Neumann, Rudi A.J.O. Dierckx, Stephen G. DiMagno, Philip H. Elsinga
Journal of Nuclear Medicine Jan 2015, 56 (1) 106-112; DOI: 10.2967/jnumed.114.145730
Jump to section
Related Articles
Cited By...
- Production of diverse PET probes with limited resources: 24 18F-labeled compounds prepared with a single radiosynthesizer
- Norepinephrine Transporter as a Target for Imaging and Therapy
- Effect of Carbidopa on 18F-FDOPA Uptake in Insulinoma: From Cell Culture to Small-Animal PET Imaging
- Molecular Imaging of Gastroenteropancreatic Neuroendocrine Tumors: Current Status and Future Directions